Valence 標誌
熱門
登入

加入到自選清單
專業圖表

Merck & Co. Inc.

NYSE: MRK · 即時價格 · USD
135.84
+0.29 (0.21%)
收盤時： Aug 14, 2026, 3:59 PM
135.04
-0.59%
盤後: 7:56 PM

Merck & Co. Inc. (MRK) Stock Price, Analysis & Data

0.21%
買價135.44
市值335.14B
營收 (ttm)66.57B
淨利（ttm）3.17B
貝塔0.21
EPS (ttm)1.25
本益比（ttm）108.67
正向 PE14.21
P/B (ttm)8.00
P/S (ttm)5.03
Earnings DateOct 29, 2026
賣價135.8
成交量4,560,728
20 日平均成交量10,256,965
打開134.43
上一頁關閉135.55
日間範圍133.40 - 135.97
52 週範圍77.58 - 135.97
分析師Buy
目標價142 (4.53%)
股利$3.4 (2.51%)
Ex-股利日期2026年9月15日

關於MRK

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veteri...

[閱讀更多]
工業 Drug Manufacturers - General
部門 Healthcare
IPO 日期 n/a
員工 73,000
證券交易所 NYSE
股票代號 MRK
網站 https://www.merck.com
完整的公司簡介

財務表現

Merck & 在 2025 年的營收為 65.01B，較前一年的 64.17B 增加 1.31%。 淨利為 18.25B，較前期增加 6.64%。

財務報表

分析師預測

根據26 分析師評等，MRK股票的平均評等為「Buy」。 12個月股價預測為142，與最新價格相比為上漲空間的4.53%。

股票預測

獲利驚喜

Merck & 已於 Aug 4, 2026 公布季度財報：
  • 營收的 $16.61B 錯過估計 $0, 與 5.07% YoY 成長.
  • EPS 的 -0.13 超出估計 0.13, 與 -106.10% YoY 下降.

    • 下次財報發布

    Merck & Co. Inc. 定於發布財報 Oct 29, 2026, 開市前。
    分析師預估營收 ... 升級
    news image

    8 小時 前 · Trefis

    AbbVie Defends Its Turf, But Leaves One Big Question Open

    AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.

    news image

    10 小時 前 · Zacks

    Can BMY's First CELMoD Approval Support Its Growth Strategy?

    Bristol Myers wins FDA accelerated approval for Zenbexus, the first CELMoD therapy, as data show it doubles MRD-negative complete response rates.

    news image

    1 日 前 · Insider Monkey

    Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine

    Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn’t always competing head-to-head; it is...

    news image

    1 日 前 · Simply Wall St.

    Merck (MRK) Stock Fair Value Edges Higher After Analysts Back Pipeline Progress

    Price target commentary for Merck has shifted toward a US$140 to US$155 range, anchored by a modest uplift in fair value from US$132.78 to US$136.85. Analysts link these higher targets to research tha...

    news image

    1 日 前 · Simply Wall St.

    Merck (MRK) Stock Looks Fully Valued Following Raised Revenue Outlook

    Merck stock has almost doubled investors' money over the past five years, yet there is a clear split between valuation tools. A Discounted Cash Flow (DCF) estimate points to a sizeable gap to intrinsi...

    第 1 頁，共 2 頁